Collegium Pharmaceutical (NASDAQ: COLL) and Taro Pharmaceutical Industries (NYSE:TARO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.
Earnings & Valuation
This table compares Collegium Pharmaceutical and Taro Pharmaceutical Industries’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Collegium Pharmaceutical||$1.71 million||381.20||-$94.17 million||($2.97)||-6.74|
|Taro Pharmaceutical Industries||$879.39 million||4.82||$456.35 million||$8.11||13.04|
Taro Pharmaceutical Industries has higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and recommmendations for Collegium Pharmaceutical and Taro Pharmaceutical Industries, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Taro Pharmaceutical Industries||0||1||0||0||2.00|
Collegium Pharmaceutical presently has a consensus price target of $24.80, suggesting a potential upside of 23.88%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, research analysts plainly believe Collegium Pharmaceutical is more favorable than Taro Pharmaceutical Industries.
This table compares Collegium Pharmaceutical and Taro Pharmaceutical Industries’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Taro Pharmaceutical Industries||44.07%||15.66%||14.18%|
Institutional and Insider Ownership
80.0% of Collegium Pharmaceutical shares are held by institutional investors. Comparatively, 13.4% of Taro Pharmaceutical Industries shares are held by institutional investors. 25.8% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Taro Pharmaceutical Industries beats Collegium Pharmaceutical on 7 of the 13 factors compared between the two stocks.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company’s owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company’s other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.